Asahi Kasei has reached 93%, including acquired shares.
Redeye has revised its forecast and valuation following TH1NG’s Q2 2024 report.
TCECUR (”TCECUR” eller ”Koncernen”) har stängt böckerna för årets andra kvartal, vilket färgats av m...
Redeye is favorable to the further validation of Nevisense in the US.
Cereno Scientific has announced its Q224 results, reflecting tangible progress with its clinical can...
Det svaga utfallet under andra kvartalet föranleder ytterligare nedjusteringar på våra prognoser.
Redeye initiates coverage of Cheffelo, the second-largest provider of meal kits in the Nordic market...
Redeye updates on Maximum Entertainment post Q2-results where topline was somewhat soft while EBITDA...
Redeye concludes that TH1NG’s reported revenues were in line with our estimates, yet the gross margi...
Solwers posted H1 revenue 3% ahead of our estimate, as organic growth was slightly positive, while w...
On 30 August 2024, Føroya Banki announced its 2026 strategy and financial targets.
Redeye states that Systemair's Q1 report only offered a couple of minor surprises.
Syncro Group har publicerat koncernens delårsrapport för det andra kvartalet 2024.
Redeye comments on BioInvent's Q2 report 2024. Positive new results from BI-1206 in lymphoma and sol...
The NTAP reimbursement decision is distinctly positive, and the CMS decision enables clinics to use ...
SmartCrafts andra kvartal visar på en fortsatt stark tillväxt i både omsättning och ARR.
Ett starkt kvartal till: Depåstoppsmodellen lyfte omsättningen kraftigt, +24%, och resultatet ökade ...
AlzeCure fortsätter att generera nya positiva data för sina projekt, vilket ökar möjligheterna när d...
Redeye comments on Ngenic’s Q2 report, which presented a y-o-y decline in both net sales and profita...
MODI reported Q2’24 sales largely in line with last year, at SEK 7.
